Publications by authors named "Fulvia D Marques"
Article Synopsis
- Myocardial infarction (MI) activates inflammatory and fibrogenic processes that impact heart remodeling; Angiotensin-(1-7) (Ang-(1-7)) shows promise as a cardioprotective agent due to its anti-inflammatory and anti-fibrotic effects.
- In this study, rats with MI were treated orally with Ang-(1-7) in hydroxypropyl β-cyclodextrin for either 7 or 60 days, resulting in improved cardiac conditions by modulating proteins associated with inflammation and mitochondrial health.
- The research revealed, for the first time, that Ang-(1-7) treatment leads to the downregulation of the CXCR4 receptor, suggesting it could be a
CGEN-856S is a novel Mas agonist. Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury. We also sought to determine whether CGEN-856S activates the underlying mechanisms related to Mas receptor activation.
View Article and Find Full Text PDFIn this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1-7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1-7) was administered for 60 days (76 μg/Kg/once a day/gavage) starting immediately before infarction.
View Article and Find Full Text PDFIn this study we evaluated the cardiac effects of a pharmaceutical formulation developed by including angiotensin (Ang)-(1-7) in hydroxypropyl β-cyclodextrin (HPβCD), in normal, infarcted, and isoproterenol-treated rats. Myocardial infarction was produced by left coronary artery occlusion. Isoproterenol (2 mg/kg, IP) was administered daily for 7 days.
View Article and Find Full Text PDF